Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of January 2021, with the report dated January 4, 2021. The filing serves as a notification to the market in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R regarding the Company's total voting rights and capital structure as of December 31, 2020.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure details:
- Issued Share Capital: 5,385,189,617 Ordinary Shares of 25 pence each.
- Treasury Shares: 355,205,950 Ordinary Shares held in Treasury.
- Total Voting Rights: 5,029,983,667.
Material Changes
The filing text does not provide comparative data against a prior period to identify material changes in share capital or voting rights. It solely establishes the baseline figures for shareholder notification calculations as of the end of 2020.
Guidance, Outlook, and Risks
The document contains no management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. Its sole purpose is to disclose the denominator for shareholder interest calculations under FCA rules.
Important Facts for Investors to Verify
- Confirm the total number of voting rights (5,029,983,667) to determine if notification thresholds for shareholding interests are met.
- Verify the number of shares held in Treasury (355,205,950) which are excluded from the voting rights count.
- Note that this filing does not contain operational or financial performance results for the period.